Cargando…

Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood

Cutaneous lupus erythematosus (CLE), the main manifestation of systemic lupus erythematosus (SLE), is driven by type I interferons (IFNs) and often only partially responds to conventional therapies. Treatment of seven SLE patients with the monoclonal antibody anifrolumab induced fast and sustained r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Günther, Claudia, Wolf, Christine, Fennen, Louisa, Rösing, Sarah, Beissert, Stefan, Aringer, Martin, Lee-Kirsch, Min Ae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551165/ https://www.ncbi.nlm.nih.gov/pubmed/37809086 http://dx.doi.org/10.3389/fimmu.2023.1253279

Ejemplares similares

Interferon blockade in lupus: effects on antiviral immunity
por: Steiger, Stefanie, et al.
Publicado: (2022)

Type I Interferon Signature in Chilblain-Like Lesions Associated with the COVID-19 Pandemic
por: Aschoff, Roland, et al.
Publicado: (2020)

Uncoupling interferons and the interferon signature explain clinical and transcriptional subsets in SLE
por: Gómez-Bañuelos, Eduardo, et al.
Publicado: (2023)

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
por: Casey, Kerry A, et al.
Publicado: (2018)

Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
Publicado: (2018)

Interferon Genes Are Influenced by 17β-Estradiol in SLE
por: Singh, Ram P., et al.
Publicado: (2021)

Blockade of Interferon‐γ Normalizes Interferon‐Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus
por: Welcher, Andrew A., et al.
Publicado: (2015)

SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus
por: Aringer, Martin, et al.
Publicado: (2003)

Cause and consequences of the activated type I interferon system in SLE
por: Eloranta, Maija-Leena, et al.
Publicado: (2016)

Interferon pathway in SLE: one key to unlocking the mystery of the disease
por: Rönnblom, Lars, et al.
Publicado: (2019)

Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway
por: Oon, Shereen, et al.
Publicado: (2016)

Regulation of B Cell Responses in SLE by Three Classes of Interferons
por: Domeier, Phillip P., et al.
Publicado: (2021)

A Novel Type I Interferon Primed Dendritic Cell Subpopulation in TREX1 Mutant Chilblain Lupus Patients
por: Eugster, Anne, et al.
Publicado: (2022)

Multiple sclerosis–like lesions and type I interferon signature in a patient with RVCL
por: Schuh, Elisabeth, et al.
Publicado: (2014)

Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis
por: Boedigheimer, Michael J, et al.
Publicado: (2017)

Corrigendum: A novel type I interferon primed dendritic cell subpopulation in TREX1 mutant chilblain lupus patients
por: Eugster, Anne, et al.
Publicado: (2022)

Clinical and immunological effects of anti-TNF therapy in systemic lupus erythematosus (SLE)
por: Aringer, M, et al.
Publicado: (2003)

Activation of the Interferon Pathway is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients
por: Ko, Kichul, et al.
Publicado: (2013)

Neutrophils and interferon-α-producing cells: who produces interferon in lupus?
por: Decker, Patrice
Publicado: (2011)

Type I Interferon Induction in Cutaneous DNA Damage Syndromes
por: Klein, Benjamin, et al.
Publicado: (2021)

Interplay of neutrophils and type I interferons in the development of end-organ damage in SLE
por: Kaplan, MJ
Publicado: (2012)

SARS-CoV-2 and interferon blockade
por: Diamond, Betty, et al.
Publicado: (2020)

Cyclin kinase inhibitors and interferons in lupus
por: Theofilopoulos, A
Publicado: (2003)

Interferon Alpha in Systemic Lupus Erythematosus
por: Niewold, Timothy B., et al.
Publicado: (2010)

SLE - Rituximab in lupus
por: Eisenberg, Robert
Publicado: (2003)

Cutaneous vasculitis in SLE
por: Kallas, Romy, et al.
Publicado: (2020)

Animal Models of Interferon Signature Positive Lupus
por: Zhuang, Haoyang, et al.
Publicado: (2015)

Interferon targeted therapies in systemic lupus erythematosus
por: Misra, Durga Prasanna, et al.
Publicado: (2017)

A Case of Systemic Lupus Erythematosus with Cutaneous Leukocytoclastic Vasculitis Mimicking Bullous SLE
por: Miyagawa, Fumi, et al.
Publicado: (2021)

Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases
por: Flint, Shaun M, et al.
Publicado: (2016)

Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood
por: Bennett, Lynda, et al.
Publicado: (2003)

Interferon-induced versus chemokine transcripts as lupus biomarkers
por: Crow, Mary K, et al.
Publicado: (2008)

Systemic lupus erythematosus and the type I interferon system
por: Rönnblom, Lars, et al.
Publicado: (2003)

Targeting type I interferons in systemic lupus erythematous
por: Bruera, Sebastian, et al.
Publicado: (2023)

Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon
Publicado: (1983)

Agonist and antagonist effects of interferon alpha and beta on activation of human macrophages. Two classes of interferon gamma receptors and blockade of the high-affinity sites by interferon alpha or beta
Publicado: (1988)

Aggregation of MAVS antiviral protein suggests a mechanism for increased type I interferon production in SLE
por: Shao, Wen-Hai, et al.
Publicado: (2014)

Vasculitis and Systemic Lupus Erythematous (SLE)
por: Cortis, Elisabetta, et al.
Publicado: (2015)

Successful Treatment of Provisional Cutaneous Mastocytosis with Interferon Alpha
por: Rosario, Andrea, et al.
Publicado: (2016)

T lymphocytes of patients with SLE lack Stat4
por: Aringer, M, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_1uhbv4m7f5b594tddqm13ajhn5